Therapeutic potential of hyporesponsive CD4+ T cells in autoimmunity

Jaxaira Maggi, Carolina Schafer, Gabriela Ubilla-Olguín, Diego Catalán, Katina Schinnerling, Juan C. Aguillón

Research output: Contribution to journalShort surveypeer-review

7 Citations (Scopus)


The interaction between dendritic cells (DCs) and T cells is crucial on immunity or tolerance induction. In an immature or semi-mature state, DCs induce tolerance through T-cell deletion, generation of regulatory T cells, and/or induction of T-cell anergy. Anergy is defined as an unresponsive state that retains T cells in an "off" mode under conditions in which immune activation is undesirable. This mechanism is crucial for the control of T-cell responses against self-antigens, thereby preventing autoimmunity. Tolerogenic DCs (tDCs), generated in vitro from peripheral blood monocytes of healthy donors or patients with autoimmune pathologies, were shown to modulate immune responses by inducing T-cell hyporesponsiveness. Animal models of autoimmune diseases confirmed the impact of T-cell anergy on disease development and progression in vivo. Thus, the induction of T-cell hyporesponsiveness by tDCs has become a promising immunotherapeutic strategy for the treatment of T-cell-mediated autoimmune disorders. Here, we review recent findings in the area and discuss the potential of anergy induction for clinical purposes.

Original languageEnglish
Article number488
JournalFrontiers in Immunology
Issue numberSEP
Publication statusPublished - 2015
Externally publishedYes


  • Autoimmune diseases
  • Hyporesponsiveness
  • Immunotherapy
  • Regulatory T cells
  • T-cell anergy
  • Tolerogenic dendritic cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Therapeutic potential of hyporesponsive CD4+ T cells in autoimmunity'. Together they form a unique fingerprint.

Cite this